(Q44982988)

English

A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up

scientific article published on 22 February 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

1 reference

based on heuristic

inferred from title

10

object named as

Anil Seth

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

author name string

Pramod K Julka

1

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Raju T Chacko

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Shona Nag

3

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Rajinder Parshad

4

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Aravindan Nair

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Chaitanyanand B Koppiker

6

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Fen Chao Richard Xue

7

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Helen Barraclough

8

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Navreet Dhindsa

9

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Anurita Majumdar

11

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Tarun Puri

12

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

22 February 2012

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

357-362

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-012-0343-4

21 January 2018

Advanced breast cancer: a phase II trial with gemcitabine

1 reference

https://api.crossref.org/works/10.1007%2FS12282-012-0343-4

21 January 2018

Single-agent gemcitabine is active in previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-012-0343-4

21 January 2018

Phase II study of neo-adjuvant gemcitabine plus epirubicin in primarily unresectable locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-012-0343-4

21 January 2018

Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS12282-012-0343-4

21 January 2018

Phase II study of gemcitabine plus cisplatin in patients with anthracycline- and taxane- pretreated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-012-0343-4

21 January 2018

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival

1 reference

https://api.crossref.org/works/10.1007%2FS12282-012-0343-4

21 January 2018

A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling

1 reference

https://api.crossref.org/works/10.1007%2FS12282-012-0343-4

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1007%2FS12282-012-0343-4

21 January 2018

A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-012-0343-4

21 January 2018

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-012-0343-4

21 January 2018

A Phase II Study of Neoadjuvant Gemcitabine Plus Doxorubicin in Stage IIIB Breast Cancer: A Preliminary Report

1 reference

https://api.crossref.org/works/10.1007%2FS12282-012-0343-4

21 January 2018

Identifiers

10.1007/S12282-012-0343-4

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44982988&oldid=2207026079"